- Home
- PCB vs DRUG Comparison
PCB vs DRUG Comparison
Compare PCB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- DRUG
- Stock Information
- Founded
- PCB 2003
- DRUG 2019
- Country
- PCB United States
- DRUG United States
- Employees
- PCB N/A
- DRUG N/A
- Industry
- PCB Major Banks
- DRUG Pharmaceuticals and Biotechnology
- Sector
- PCB Finance
- DRUG Health Care
- Exchange
- PCB Nasdaq
- DRUG Nasdaq
- Market Cap
- PCB 315.4M
- DRUG 364.8M
- IPO Year
- PCB N/A
- DRUG N/A
- Fundamental
- Price
- PCB $22.07
- DRUG $67.12
- Analyst Decision
- PCB Hold
- DRUG Strong Buy
- Analyst Count
- PCB 2
- DRUG 8
- Target Price
- PCB $24.50
- DRUG $83.00
- AVG Volume (30 Days)
- PCB 29.2K
- DRUG 169.5K
- Earning Date
- PCB 10-23-2025
- DRUG 12-30-2025
- Dividend Yield
- PCB 3.62%
- DRUG N/A
- EPS Growth
- PCB 43.50
- DRUG N/A
- EPS
- PCB 2.41
- DRUG N/A
- Revenue
- PCB $107,743,000.00
- DRUG N/A
- Revenue This Year
- PCB $21.55
- DRUG N/A
- Revenue Next Year
- PCB $8.65
- DRUG N/A
- P/E Ratio
- PCB $9.16
- DRUG N/A
- Revenue Growth
- PCB 13.61
- DRUG N/A
- 52 Week Low
- PCB $16.00
- DRUG $23.18
- 52 Week High
- PCB $22.45
- DRUG $70.23
- Technical
- Relative Strength Index (RSI)
- PCB 58.70
- DRUG 66.07
- Support Level
- PCB $20.97
- DRUG $56.65
- Resistance Level
- PCB $21.81
- DRUG $60.40
- Average True Range (ATR)
- PCB 0.54
- DRUG 3.65
- MACD
- PCB 0.02
- DRUG 0.77
- Stochastic Oscillator
- PCB 69.43
- DRUG 88.23
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.